Potential Shift of KRASG12C Inhibitors to the Front-line Setting

Two experts discuss the potential role of using adagrasib and sotorasib in the front-line setting and how it might shift the treatment paradigm for patients with KRASG12C-mutated NSCLC with CNS metastases.

Related Videos
Expert on lung cancer
Expert on NSCLC
Expert on NSCLC
Expert on NSCLC
Chandler H. Park, MD, an expert on renal cell carcinoma
Edward B. Garon, MD, MS, an expert on lung cancer
Related Content